Zeitouni, Michel
Kerneis, Mathieu
Lattuca, Benoit
Guedeney, Paul
Cayla, Guillaume
Collet, Jean-Philippe
Montalescot, Gilles
Silvain, Johanne
Article History
First Online: 4 March 2019
Compliance with Ethical Standards
:
: No external funding was used in the preparation of this manuscript.
: M. Zeitouni has received research grants from Institut Servier and Federation Française de Cardiologie. M. Kerneis has received research grants from Sanofi, Institut Servier, and Federation Française de Cardiologie. B. Lattuca has received research grants from Biotronik, Daiichi Sankyo, and Fédération Française de Cardiologie; consultant fees from Daiichi Sankyo and Eli Lilly; and lecture fees from AstraZeneca and Novartis. P. Guedeney has no financial relationships or conflicts of interest. G. Cayla has received consulting and lecture fees from Abbott Vascular, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Boston Scientific, CLS Behring, Daiichi Sankyo, Eli Lilly, Iroko Cardio, Novartis, and Pfizer. J.P. Collet has received research grants or honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Fédération Française de Cardiologie, Lead-Up, Medtronic, MSD, Sanofi-Aventis, and WebMD. G. Montalescot has received research grants or honorarium from Abbott, Amgen, Actelion, AstraZeneca, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women’s Hospital, Cardiovascular Research Foundation, Daiichi Sankyo, Idorsia, Lilly, Europa, Elsevier, Fédération Française de Cardiologie, ICAN, Medtronic, <i>Journal of the American College of Cardiology</i>, Lead-Up, Menarini, MSD, Novo Nordisk, Pfizer, Sanofi, Servier, The Mount Sinai School, TIMI Study Group, and WebMD. J. Silvain has received consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Gilead Science and Sanofi-Aventis, speaker honorariums from AstraZeneca, Amgen, Bayer, Algorythm, and Sanofi-Aventis and travel support from Amgen, AstraZeneca, Bayer, and Bristol-Myers Squibb.